Skip to main content

Table 2 Multivariate Cox proportional hazards regression analyses for overall and cancer-specific mortality in patients with leiomyosarcoma or carcinosarcoma

From: Outcome of adjuvant radiotherapy after total hysterectomy in patients with uterine leiomyosarcoma or carcinosarcoma: a SEER-based study

  Leiomyosarcoma Carcinosarcoma
Overall a Cancer-specific b Overall c Cancer-specific d
Variables aHR (95% CI) P-value aHR (95% CI) P-value aHR (95% CI) P-value aHR (95% CI) P-value
Adjuvant radiotherapy
 No treatment reference   reference   reference   reference  
 EBRT alone 0.90 (0.54, 1.51) 0.697 0.91 (0.51, 1.64) 0.760 0.72 (0.53, 0.99) 0.042 0.78 (0.54, 1.14) 0.199
 Brachytherapy alone 0.57 (0.14, 2.31) 0.429 0.47 (0.07, 3.38) 0.452 0.55 (0.37, 0.80) 0.002 0.51 (0.31, 0.84) 0.009
 Combination radiotherapy e NA NA NA NA 0.47 (0.29, 0.77) 0.003 0.53 (0.29, 0.95) 0.034
Age
 < 60 years reference     reference    
 ≥ 60 years 1.55 (1.11, 2.18) 0.011    1.74 (1.27, 2.37) 0.001   
AJCC Stage
 Stage I reference   reference   reference   reference  
 Stage II 1.82 (1.15, 2.89) 0.011 1.85 (1.09, 3.12) 0.022 1.06 (0.67, 1.69) 0.802 1.10 (0.61, 1.98) 0.758
 Stage III 3.07 (2.01, 4.69) < 0.001 3.21 (2.02, 5.13) < 0.001 2.36 (1.88, 2.97) < 0.001 2.57 (1.93, 3.42) < 0.001
Grade
 Grade 1 reference        
 Grade 2 1.58 (0.18, 13.60) 0.679       
 Grade 3 7.17 (0.97, 52.86) 0.053       
 Undifferentiated/anaplastic 5.08 (0.69, 37.09) 0.110       
Tumor size
  ≤ 50 mm    reference   reference   reference  
  > 50 mm    2.98 (1.38, 6.45) 0.006 1.96 (1.50, 2.57) < 0.001 2.07 (1.46, 2.93) < 0.001
Lymphadenectomy
 No      reference   reference  
 Yes      0.61 (0.47, 0.78) < 0.001 0.61 (0.45, 0.84) 0.003
  1. aHR adjusted hazard ratio, CI confidence interval, EBRT external beam radiation therapy, AJCC American Joint Committee on Cancer
  2. aModel was adjusted by age group, and stage, grade
  3. bModel was adjusted by stage, and tumor size
  4. cModel was adjusted by age group, stage, tumor size, and lymphadenectomy
  5. dModel was adjusted stage, tumor size, and lymphadenectomy
  6. eCombination radiotherapy: combination of EBRT and either radioactive implants or radioisotopes
  7. NA, not available because no patient died during the study period
  8. Unknown data for adjuvant radiotherapy, AJCC stage, grade, tumor size, and lymphadenectomy status were not shown in the table
  9. Bold text indicates a significant difference with a p-value less than 0.05 compared to the reference group